Licensing deal index shows re-emergence of late-stage deals

28 October 2014

Licensing deals among biotech companies have recently shown a healthy surge, especially in later stages. The sector has experienced a big jump in the number of deals and average payments for Phase III and approved products, according to London-based law firm Morrison & Foerster’s BioMeter Index.

This quarter’s figures are the strongest since the company created the BioMeter Index. The report shows seven Phase III transactions with an average upfront payment of $83.3 million, and five approved-product transactions with an average value of $86.7 million for the third quarter.

Morrison and Foerster attribute this to pharma companies switching from the focus on early-stage assets to pursuing products closer to commercialization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK